
Sarepta Therapeutics, Inc.
SRPTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 6, 2026 | Robert W. Baird | Brian Skorney | $18.00(+2%) | $17.57 | StreetInsider |
| Oct 8, 2026 | RBC Capital | $17.00(-2%) | $17.43 | TheFly | |
| Jul 27, 2026 | Morgan Stanley | $25.00(+54%) | $16.28 | TheFly | |
| Jul 9, 2026 | Piper Sandler | $20.00(-1%) | $20.21 | TheFly | |
| Jul 8, 2026 | Wolfe Research | $27.00(+34%) | $20.21 | TheFly | |
| May 15, 2026 | Evercore ISI | $19.00(+4%) | $18.20 | TheFly | |
| Mar 26, 2026 | Deutsche Bank | $14.00(-35%) | $21.68 | TheFly | |
| Mar 26, 2026 | Wedbush | $35.00(+61%) | $21.68 | TheFly | |
| Mar 12, 2026 | Mizuho Securities | Uy Ear | $31.00(+82%) | $17.04 | StreetInsider |
| Mar 3, 2026 | Loop Capital Markets | Ilya Zubkov | $25.00(+58%) | $15.87 | StreetInsider |
| Mar 3, 2026 | Jefferies | Andrew Tsai | $30.00(+88%) | $15.98 | StreetInsider |
| Jan 27, 2026 | Robert W. Baird | $22.00(-4%) | $22.80 | TheFly | |
| Dec 9, 2025 | Wedbush | $32.00(+46%) | $21.86 | TheFly | |
| Nov 25, 2025 | Bernstein | $20.00(+6%) | $18.91 | TheFly | |
| Nov 5, 2025 | Barclays | $20.00(+23%) | $16.20 | TheFly | |
| Nov 5, 2025 | Mizuho Securities | Uy Ear | $26.00(+60%) | $16.20 | StreetInsider |
| Nov 4, 2025 | Robert W. Baird | Brian Skorney | $15.00(-39%) | $24.45 | StreetInsider |
| Oct 30, 2025 | Piper Sandler | Biren Amin | $16.00(-32%) | $23.45 | TheFly |
| Sep 9, 2025 | Leerink Partners | Joseph Schwartz | $15.00(-15%) | $17.57 | TheFly |
| Aug 21, 2025 | Barclays | $22.00(+10%) | $20.06 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| RBC Capital | maintain | Sector Perform | Nov 6, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 8, 2026 |
| HC Wainwright & Co. | maintain | Sell | Oct 5, 2026 |
| JP Morgan | maintain | Neutral | Sep 30, 2026 |
| Needham | maintain | Underperform | Sep 28, 2026 |
| Wolfe Research | upgrade | Peer Perform →Outperform | Jul 9, 2026 |
| Piper Sandler | maintain | Neutral | Jul 9, 2026 |
| HC Wainwright & Co. | maintain | Sell | Apr 16, 2026 |
| Citigroup | maintain | Sell | Mar 26, 2026 |
| Needham | maintain | Underperform | Mar 26, 2026 |
| Oppenheimer | maintain | Outperform | Mar 19, 2026 |
| Mizuho | maintain | Outperform | Mar 13, 2026 |
| Citigroup | maintain | Sell | Mar 10, 2026 |
| HC Wainwright & Co. | maintain | Sell | Mar 2, 2026 |
| Wells Fargo | maintain | Overweight | Feb 27, 2026 |
| HC Wainwright & Co. | maintain | Sell | Jan 27, 2026 |
| Wedbush | maintain | Outperform | Jan 23, 2026 |
| HC Wainwright & Co. | maintain | Sell | Jan 14, 2026 |
| Guggenheim | maintain | Buy | Nov 5, 2025 |
| Barclays | maintain | Equal Weight | Nov 5, 2025 |
| Wells Fargo | maintain | Overweight | Nov 5, 2025 |
| Mizuho | upgrade | Neutral →Outperform | Nov 5, 2025 |
| Baird | maintain | Neutral | Nov 4, 2025 |
| Piper Sandler | maintain | Neutral | Oct 30, 2025 |
| BMO Capital | upgrade | Market Perform →Outperform | Sep 22, 2025 |
Earnings History
Next report: Feb 24, 2027 · EPS est. $-0.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $0.13 | $0.07 | $381.4M | $352.2M |
| Aug 5, 2026 | $-0.05 | $0.22 | $401.3M | $366.4M |
| May 6, 2026 | $3.16 | $0.98 | $730.8M | $474.2M |
| Feb 25, 2026 | $-3.58 | $-1.03 | $442.9M | $369.6M |
| Nov 3, 2025 | $-1.80 | $-0.73 | $399.4M | $335.8M |
| Aug 6, 2025 | $2.02 | $0.83 | $611.1M | $530.7M |
| May 6, 2025 | $-4.60 | $-0.87 | $744.9M | $687.5M |
| Feb 26, 2025 | $1.50 | $1.38 | $658.4M | $631.0M |
News
Sarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick Moss - Executive VP & Chief Commercial Officer Louise Rodino-Klapac - President of Research & Development and Technical Operations Ryan Wong - Executive VP & CFO James Richardson - Executive VP & Chief Medical Officer Conference Call Participants Adhiraj Chauhan - JPMorgan Chase &…
Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drug franchise.
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026. “After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opport.
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation from the Guggenheim conference will be webcast live under the in…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations.
Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Profitability This table compares Protagonist Therapeutics and Sarepta
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA (siRNA) program for the treatment of myotonic dystrophy type 1 (DM1), can directly reduce pathogenic DMPK transcripts within the nucleus, where the molecular drivers o.
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. A.
Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report)'s stock had its "sell" rating reissued by HC Wainwright in a research report issued on Monday, MarketBeat.com reports. They currently have a $5.00 target price on the biotechnology company's stock. HC Wainwright's target price points to a potential downside of 71.43% from the stock's previous close. A number
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy. In ambulatory patients treated at ages 8 to 12, an age range in which functional decline becomes even m.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan. Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta'.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas. Sarepta will present seven posters at NMSG. Among the analyses are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvov.
Squarepoint Ops LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,026 shares of the biotechnology company's stock after selling 48,276 shares during the
Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript